CBIO
Crescent Biopharma, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$581.53M
P/E Ratio
—
EPS
$-12.81
Beta
—
52W High
$29.00
52W Low
$8.72
50-Day MA
$11.81
200-Day MA
$12.75
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Crescent Biopharma, Inc.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement regulation. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $10.84M |
| Gross Profit (TTM) | $10.84M |
| EBITDA | $-152.55M |
| Operating Margin | -844.00% |
| Return on Equity | -160.70% |
| Return on Assets | -69.20% |
| Revenue/Share (TTM) | $0.90 |
| Book Value | $5.99 |
| Price-to-Book | 2.95 |
| Price-to-Sales (TTM) | 53.63 |
| EV/Revenue | 35.08 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $27.56M |
| Float | $14.42M |
| % Insiders | 5.82% |
| % Institutions | 87.53% |
Historical Volatility
HV 10-Day
103.62%
HV 20-Day
103.16%
HV 30-Day
91.42%
HV 60-Day
91.77%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($29.29 target)
1
Strong Buy8
BuyData last updated: 4/10/2026